Ioxilan
Ioxilan is a diagnostic contrast agent.
Snapshot
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Ioxilan is a diagnostic contrast agent.[1] It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. It was marketed in the US under the trade name Oxilan by Guerbet, L.L.C., but was discontinued in 2017.[2]
Mechanism of action
edit edit sourceIoxilan is an iodinated contrast agent.[2]
References
edit edit source- ^ Cheng KT (December 2007). "Ioxilan carbonate particles". Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US). PMID 20641969. Wikipedia revision 1365020062, retrieved 2026-11-18
- ^ a b Oxilan FDA Professional Drug Information. Accessed 2021-04-07. Wikipedia revision 1365020062, retrieved 2026-11-18
Water insoluble
- Ethiodized oil (= Ethyl esters of iodised fatty acids, lipiodol)
- Iopydol
- Propyliodone
- Iofendylate‡
- Microspheres of human albumin
- Microparticles of galactose
- Perflenapent
- Microspheres of phospholipids
- Sulfur hexafluoride
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Text derived from https://en.wikipedia.org/w/index.php?oldid=1365020062 under CC BY-SA 4.0; modifications have been made.